13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001856083
Total reported value
$6.9B
$6.9B
65 檔
10.8%
The Q1 2024 SEC filing reveals that Deep Track Capital, LP held a total portfolio value of $6.9B, covering 65 public equity positions.
During Q1 2024, Deep Track Capital, LP's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
In terms of portfolio concentration, the top 5 core holdings (including SWTXUSD, AMGN, APGE) accounted for 10.8% of total reported equity market value during Q1 2024.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | SWTXUSD | Springworks Therapeutics Inc | Stock-Other | 4.91% | — | -14.37% | |
| 2 | AMGN | Amgen Inc | Stock-Healthcare | 4.48% | — | — | |
| 3 | APGE | Apogee Therapeutics Inc | Stock-Other | 4.42% | -0.39% | EXIT | |
| 4 | INSM | Insmed Inc | Stock-Healthcare | 3.72% | — | -10.59% | |
| 5 | DYN | Dyne Therapeutics Inc | Stock-Other | 3.70% | -0.11% | +127.77% | |
| 6 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 3.56% | +3.61% | NEW | |
| 7 | GH | Guardant Health Inc | Stock-Healthcare | 3.55% | +2.37% | +20.00% | |
| 8 | ARGX | Argenx Se - Adr | Stock-Healthcare | 3.38% | — | — | |
| 9 | ITCIEUR | Intra-cellular Therapies Inc | Stock-Other | 3.32% | — | -16.23% | |
| 10 | NTLA | Intellia Therapeutics Inc | Stock-Other | 3.32% | — | +87.15% | |
| 11 | OCUL | Ocular Therapeutix Inc | Stock-Other | 3.32% | +0.09% | +37.82% | |
| 12 | DVAX | Dynavax Technologies CORP | Stock-Other | 3.25% | — | +28.88% | |
| 13 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 2.98% | -0.55% | +30.47% | |
| 14 | GERN | Geron CORP | Stock-Other | 2.88% | -0.77% | EXIT | |
| 15 | AUTL | Autolus Therapeutics PLC | Stock-Other | 2.79% | — | +28.67% | |
| 16 | FDMT | 4d Molecular Therapeutics In | Stock-Other | 2.77% | — | +32.84% | |
| 17 | ALKS | Alkermes plc | Stock-Healthcare | 2.71% | +0.98% | -12.50% | |
| 18 | BCYC | Bicycle Therapeutics Plc-adr | Stock-Other | 2.49% | — | — | |
| 19 | PLRX | Pliant Therapeutics Inc | Stock-Other | 2.45% | — | — | |
| 20 | BRD1EUR | Mind Medicine Mindmed Inc | Stock-Other | 1.80% | — | — | |
| 21 | ABVX | Abivax Sa-adr | Stock-Other | 1.76% | — | — | |
| 22 | VRDN | Viridian Therapeutics Inc | Stock-Other | 1.73% | +0.51% | -4.84% | |
| 23 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 1.71% | +0.15% | +9.96% | |
| 24 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 1.68% | -2.98% | EXIT | |
| 25 | ANIP | Ani Pharmaceuticals Inc | Stock-Other | 1.63% | -0.75% | EXIT | |
| 26 | TVTX | Travere Therapeutics Inc | Stock-Other | 1.63% | — | — | |
| 27 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 1.47% | — | — | |
| 28 | KYMR | Kymera Therapeutics Inc | Stock-Other | 1.45% | — | — | |
| 29 | IVVD | Invivyd Inc | Stock-Other | 1.39% | — | — | |
| 30 | SYRE | Spyre Therapeutics Inc | Stock-Other | 1.32% | — | -37.86% | |
| 31 | NRIX | Nurix Therapeutics Inc | Stock-Other | 1.26% | +1.12% | — | |
| 32 | ✓ | Hillevax Inc | Stock-Other | 1.23% | — | -11.29% | |
| 33 | EDIT | Editas Medicine Inc | Stock-Other | 1.17% | — | +0.99% | |
| 34 | FATE | Fate Therapeutics Inc | Stock-Other | 1.17% | — | — | |
| 35 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 1.15% | -0.92% | EXIT | |
| 36 | ✓ | Engene Holdings Inc | Stock-Other | 1.09% | -0.49% | EXIT | |
| 37 | TRML | Tourmaline Bio Inc | Stock-Other | 1.05% | — | -12.14% | |
| 38 | OLMA | Olema Pharmaceuticals Inc | Stock-Other | 1.05% | +0.27% | NEW | |
| 39 | SLN | Silence Therapeutics Plc-adr | Stock-Other | 1.02% | — | -15.77% | |
| 40 | PACB | Pacific Biosciences Of Calif | Stock-Other | 0.75% | — | — | |
| 41 | CYBNEUR | Cybin Inc | Stock-Other | 0.69% | — | — | |
| 42 | ALEC | Alector Inc | Stock-Other | 0.65% | — | — | |
| 43 | NUVL | Nuvalent Inc-a | Stock-Other | 0.59% | +0.91% | -39.00% | |
| 44 | AGENEUR | Agenus Inc | Stock-Other | 0.53% | — | — | |
| 45 | PYXS | Pyxis Oncology Inc | Stock-Other | 0.51% | — | — | |
| 46 | NKTREUR | Nektar Therapeutics | Stock-Other | 0.49% | — | — | |
| 47 | IMVT | Immunovant Inc | Stock-Other | 0.46% | +0.56% | -50.66% | |
| 48 | NMRA | Neumora Therapeutics Inc | Stock-Other | 0.39% | — | — | |
| 49 | RPTX | Repare Therapeutics Inc | Stock-Other | 0.36% | — | -10.30% | |
| 50 | SRRK | Scholar Rock Holding CORP | Stock-Other | 0.35% | — | -32.80% |
According to official SEC Form 13F filings, Deep Track Capital, LP reported a total U.S. public equity portfolio value of $6.9B across 65 disclosed positions in Q1 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
During Q1 2024, Deep Track Capital, LP's top holdings by market value included SWTXUSD (4.9%)、AMGN (4.5%)、APGE (4.4%). The largest single position, SWTXUSD, represented 4.9% of total portfolio value.
In Q1 2024, Deep Track Capital, LP made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.